Adaptive Biotechnologies Corporation (NASDAQ:ADPT) finished Wednesday with a subtraction of -$0.24 to close at $6.91, a downside of -3.36 percent. An average of 1,247,000 shares of common stock have been traded in the last five days. There was a fall of -$0.18 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 1,035,200 shares traded, while the 50-day average volume stands at 1,050,154.
ADPT stock has decreased by -15.11% in the last month. The company shares reached their 1-month lowest point of $6.72 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $5.95 and a high of $29.17 in 52 weeks. It has reached a new high 1 time so far this year and lost -75.37% or -$21.15 in price. In spite of this, the price is down -76.31% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
ADPT stock investors should be aware that Adaptive Biotechnologies Corporation (ADPT) stock had its last reported insider trading activity 43 days ago on Nov 16. In this transaction, the insider spent $8,506. Chief Commercial Officer, MRD, SOOD NITIN, disposed of 31,066 shares at a price of $8.00 on Nov 01. The insider now owns more than $248,528 worth of shares. Prior to that, Chief Operating Officer ADAMS R MARK went on to Sale 2,284 shares at $7.13 each on Oct 10. An amount of $16,285 was transacted.
Adaptive Biotechnologies Corporation (ADPT) stock’s beta is 1.07. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.32, the price-to-book (PB) ratio at 2.03.
The quick ratio of Adaptive Biotechnologies Corporation for the three months ended September 29 was 5.30, and the current ratio was 5.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $105.04 million compared to revenue of $154.34 million.
For the three-month period that ended September 29, Adaptive Biotechnologies Corporation had $290.53 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$45.28 million in the quarter, while revenues were shrunk -23.45%. The analyst consensus anticipated Adaptive Biotechnologies Corporation’s latest quarter earnings to come in at -$0.38 per share, but it turned out to be -$0.32, a 15.80% surprise. For the quarter, EBITDA amounted to -$39.64 million. Shareholders own equity worth $143.01 million.
From a technical analysis perspective, let’s take a brief look at Adaptive Biotechnologies Corporation (ADPT) price momentum. RSI 9-day as of the close on 28 December was 35.51%, suggesting the stock is Neutral, with historical volatility in this time frame at 93.02%.
As of today, ADPT’s price is $7.53 -2.54% or -$0.18 from its 5-day moving average. ADPT is currently trading -12.09% lower than its 20-day SMA and -39.65% lower than its 100-day SMA. However, the stock’s current price level is +1.17% above the SMA50 and -31.72% below the SMA200.
The stochastic %K and %D were 12.15% and 18.00%, respectively, and the average true range (ATR) was 0.63. With the 14-day stochastic at 7.06% and the average true range at 0.64, the RSI (14) stands at 40.13%. The stock has reached -0.39 on the 9-day MACD Oscillator while the 14-day reading was at -0.74.
Piper Sandler upgraded Adaptive Biotechnologies Corporation (NASDAQ: ADPT) to a an Overweight rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Adaptive Biotechnologies Corporation (ADPT) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell ADPT, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is ADPT’s price target for the next 12 months?
Analysts predict a range of price targets between $7.00 and $18.00, with a median target of $13.00. Taking a look at these predictions, the average price target given by analysts for Adaptive Biotechnologies Corporation (ADPT) stock is $13.00.